Hemogenyx Pharmaceuticals PLC (LSE: HEMO, OTC: HOPHF) saw its shares surge 26% on Monday after announcing a strategic manufacturing partnership to advance its experimental CAR-T therapy, HG-CT-1, for acute myeloid leukaemia (AML).
The London-listed biotech has partnered with Made Scientific, a US-based contract manufacturer specialising in cell therapies, to scale up production of HG-CT-1. The therapy is currently in early-stage clinical trials for adults with relapsed or treatment-resistant AML.
Under the agreement, Made Scientific will oversee technology transfer and manufacturing at its New Jersey facilities, which are equipped to handle both clinical and potential commercial supply.
Hemogenyx said the deal is expected to accelerate its Phase I trial and may support the future inclusion of paediatric patients.
Chief executive Vladislav Sandler described the partnership as pivotal, stating that Made Scientific’s expertise would be “instrumental in driving the continued progress of this potentially breakthrough therapy.”
The company added that early trial data have shown promising safety and efficacy signals.
